Sugi Predict

Sugi Predict / Compounds / SCHEMBL1403852

SCHEMBL1403852

SCHEMBL1403852

Cc1ccnnc1C(N)=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SIRT3 Q9NTG7 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ LCK P06239 2/20 0.39
▸ BTK Q06187 2/20 0.39
▸ LIMK1 P53667 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ ADORA3 P0DMS8 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ ADORA2A P29274 1/20 0.36
▸ ADORA2B P29275 1/20 0.36
▸ ADORA1 P30542 1/20 0.36
▸ KAT2B Q92831 1/20 0.36
▸ IKBKB O14920 2/20 0.36
▸ MAP2K3 P46734 3/20 0.34
▸ MAP2K6 P52564 1/20 0.34
▸ MAP3K19 Q56UN5 1/20 0.34
▸ NEK10 Q6ZWH5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22290211 0.86 SIRT3 (0.38) SIRT3TDP1LCKBTKLIMK1
SCHEMBL30205008 0.86 SIRT3 (0.38) SIRT3TDP1LCKBTKLIMK1
SCHEMBL30431049 0.86 SIRT3 (0.38) SIRT3TDP1LCKBTKLIMK1
SCHEMBL30937682 0.81 KCNJ1 (0.40) SIRT3TDP1KMT2AIKBKB
SCHEMBL354481 0.81 HCAR2 (0.39) SIRT3TDP1KMT2AKDM4ELMNA
SCHEMBL7020095 0.78 MEN1 (0.35) SIRT3TDP1LCKBTKMEN1
SCHEMBL19691158 0.77 KMT2A (0.37) SIRT3LCKBTKMEN1KMT2A
SCHEMBL3145246 0.77 MAP2K3 (0.44) SIRT3TDP1LCKBTKMEN1
SCHEMBL30591940 0.77 MAP2K3 (0.44) SIRT3TDP1LCKBTKMEN1
SCHEMBL28309038 0.77 SIRT3 (0.38) SIRT3TDP1LCKBTKMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113227071-B Amide-substituted heterocyclic compounds for the treatment of disorders associated with modulation of IL-12, IL-23 and/or IFN-alpha 百时美施贵宝公司 2024-06-25 — — CN claimed
CN-117794912-A Substituted heterocyclic compounds 百时美施贵宝公司 2024-03-29 — — CN claimed
US-20240059671-A1 TYROSINE KINASE 2 (TYK2) DEGRADATION COMPOUNDS AND METHODS OF USE CULLGEN (SHANGHAI) , INC. (CN) 2024-02-22 — — US claimed
CN-117321043-A Substituted heterocyclic compounds 百时美施贵宝公司 2023-12-29 — — CN claimed
CN-117321045-A Substituted heterocyclic compounds 百时美施贵宝公司 2023-12-29 — — CN claimed
CN-111936486-B Heterocyclic compounds comprising pyridine as modulators of IL-12, IL-23 and/or IFN alpha responses 百时美施贵宝公司 2023-09-22 — — CN claimed
CN-111315737-A Sulfonylpyridinylalkylamide substituted heteroaryl compounds 百时美施贵宝公司 2020-06-19 — — CN claimed
US-10383871-B2 Azetidine derivatives VERNALIS (R&D) LTD. (GB) 2019-08-20 — — US claimed
US-20170196864-A1 Azetidine Derivatives VERNALIS DEVELOPMENT LIMITED (GB) 2017-07-13 — — US claimed
US-9475800-B2 Azetidine derivatives VERNALIS (R&D) LTD. (GB) 2016-10-25 — — US claimed
US-20150183769-A1 Azetidine Derivatives VERNALIS DEVELOPMENT LIMITED (GB) 2015-07-02 — — US claimed
US-9006269-B2 Azetidine derivatives VERNALIS (R&D) LTD. (GB) 2015-04-14 — — US claimed
US-20130331371-A1 Azetidine Derivatives VERNALIS (R&D) LTD. (GB) 2013-12-12 — — US claimed
US-8450346-B2 Azetidine derivatives as FAAH inhibitors VERNALIS (R&D) LTD. (GB) 2013-05-28 — — US claimed
US-20260055121-A1 TYK2 INHIBITORS AND USES THEREOF SUDO BIOSCIENCES LTD (GB) 2026-02-26 — — US disclosed
CN-119730846-A Kinase modulators and methods of use thereof 神经元23公司 2025-03-28 — — CN disclosed
US-20250011291-A1 KEAP1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2025-01-09 — — US disclosed
EP-2265578-A1 AZETIDINE DERIVATIVES Vernalis (R&D) Ltd. (GB) 2010-12-29 — — EP disclosed
WO-2009109743-A1 AZETIDINE DERIVATIVES VERNALIS (R&D) LTD. (GB) 2009-09-11 — — WO disclosed
US-20070208005-A1 TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR GLAXO GROUP LIMITED (GB) 2007-09-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130331371-A1 Azetidine Derivatives FAAH2, FAAH, APEH SIRT3 2552/4885TDP1 3265/4885LCK 4668/4885
US-20150183769-A1 Azetidine Derivatives FAAH2, FAAH, APEH SIRT3 2552/4885TDP1 3265/4885LCK 4668/4885
US-20170196864-A1 Azetidine Derivatives FAAH2, FAAH, APEH SIRT3 2491/4885TDP1 3256/4885LCK 4686/4885
US-20250011291-A1 KEAP1 INHIBITORS AND USES THEREOF KEAP1, NFE2L2, NQO1 SIRT3 321/4885TDP1 4107/4885LCK 4230/4885
US-20240059671-A1 TYROSINE KINASE 2 (TYK2) DEGRADATION COMPOUNDS AND METHODS OF USE TYK2, ERBB2, PTK2B SIRT3 4195/4885TDP1 242/4885LCK 7/4885
US-10383871-B2 Azetidine derivatives FAAH2, FAAH, APEH SIRT3 2491/4885TDP1 3256/4885LCK 4686/4885
US-20260055121-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, CSNK2A3, CSNK2B SIRT3 1377/4885TDP1 843/4885LCK 65/4885
US-20070208005-A1 TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR HRH3, HRH4, HRH1 SIRT3 1948/4885TDP1 3389/4885LCK 1328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.